Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endothelin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43893   clinical trials with a EudraCT protocol, of which   7300   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    104 result(s) found for: Endothelin. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2005-001193-28 Sponsor Protocol Number: AMB-320/321-E Start Date*: 2005-11-08
    Sponsor Name:Myogen, Inc
    Full Title: ARIES-320/321-E “A Long-Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 or AMB-321"
    Medical condition: Pulmonary Arterial Hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003140-27 Sponsor Protocol Number: V1.0/OPHT-020606 Start Date*: 2006-07-25
    Sponsor Name:Department of Clinical Pharmacology
    Full Title: Effects of non-specific Endothelin-A receptor blockade on ocular blood flow in patients with glaucoma
    Medical condition: patients with primary open angle glaucoma in comparision to a healthy control group.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-000812-29 Sponsor Protocol Number: AMB 320 Start Date*: 2005-09-21
    Sponsor Name:Myogen, Inc.
    Full Title: Ambrisentan in PAH - A Phase III, Randomised, Double- Blind, Placebo- Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects with Pulmonary Arterial Hypertension
    Medical condition: Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    7.0 10037400 low
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) BE (Completed) IT (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000848-14 Sponsor Protocol Number: 38RC12.228 Start Date*: 2014-07-23
    Sponsor Name:Centre Hospitalier Universitaire de Grenoble
    Full Title: Endothelin and Ischemic optic Neuropathy study group
    Medical condition: Endothelin and Ischemic Optic Neuropathy study group
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-000701-61 Sponsor Protocol Number: BIRD-1 250705 Start Date*: 2005-11-29
    Sponsor Name:University College London
    Full Title: An open label trial of the dual specificity endothelin receptor antagonist bosentan in established scleroderma renal crisis
    Medical condition: Scleroderma renal crisis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-005679-33 Sponsor Protocol Number: KKSH-042 Start Date*: 2011-01-20
    Sponsor Name:Medizinische Fakultät der Martin-Luther-Universität Halle-Wittenberg
    Full Title: Influence of the selective endothelin receptor-blocker Ambrisetan on the portal pressure in patients with cirrhosis
    Medical condition: Portal hypertension and hepatic cirrhosis
    Disease: Version SOC Term Classification Code Term Level
    16.1 10019805 - Hepatobiliary disorders 10036200 Portal hypertension PT
    16.1 10019805 - Hepatobiliary disorders 10009213 Cirrhosis of liver LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003482-68 Sponsor Protocol Number: BAY 63-2521/12934 Start Date*: 2008-11-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: Randomized, double-blind, placebo-controlled, multi-centre, multi-national study to evaluate the efficacy and safety of oral BAY 63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg tid) in patients with symptom...
    Medical condition: Pulmonary Arterial Hypertension (PAH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Prematurely Ended) AT (Completed) ES (Completed) NL (Completed) FR (Completed) SE (Completed) GB (Completed) CZ (Completed) DK (Completed) BE (Completed) IT (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2010-023908-27 Sponsor Protocol Number: AC-052-427 Start Date*: 2011-03-16
    Sponsor Name:Actelion Pharmaceuticals Nederland bv
    Full Title: Effects of bosentan in a HOMogenEous population of SSc subjects with a predefined restriction of blood flow in the hands (HOME)
    Medical condition: Digital Ulcera in Systemic Sclerodermia patients
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053400 Endothelin increased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2009-014137-25 Sponsor Protocol Number: VARDENAFIL&DIABETES Start Date*: 2009-12-15
    Sponsor Name:Unita` Operativa di Endocrinologia e Malattie del Metabolismo
    Full Title: Monitoring of endothelial dysfunction during chronic administration of vardenafil in patients with type 2 diabetes mellitus: A longitudinal, randomised, placebo-controlled, double blind, phase II b...
    Medical condition: patients affected by type 2 Diabetes mellitus and affected by mild or severe ED
    Disease: Version SOC Term Classification Code Term Level
    12.0 10045248 Type II diabetes mellitus with other specified manifestations LLT
    Population Age: Adults Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004533-21 Sponsor Protocol Number: 03602 Start Date*: 2010-06-25
    Sponsor Name:ICIN
    Full Title: The role of Bosentan in fontan patients: improvement of aerobic capacity
    Medical condition: To study whether bosentan (endothelin receptor inhibitor) improves aerobic capacity (VO2max) and exercise performance in adult patients with a Fontan operation.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064911 Pulmonary arterial hypertension LLT
    Population Age: Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004072-35 Sponsor Protocol Number: 18-AOIP-01 Start Date*: 2019-02-13
    Sponsor Name:CHU de Nice
    Full Title: Study of the value of early treatment with an endothelin inhibitor (Bosentan) in patients with sudden blindness secondary to giant cell arteritis
    Medical condition: giant cell arteritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003232 Arteritis coronary PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-004391-36 Sponsor Protocol Number: AC-052-402 Start Date*: 2005-05-23
    Sponsor Name:Actelion Pharmaceuticals Ltd.
    Full Title: A multicenter, open-label, single-arm safety study to investigate the effects of chronic TRACLEER® treatment on testicular function in male patients with pulmonary arterial hypertension
    Medical condition: Many endothelin receptor antagonists have profound effects on the histology and function of the testes in animals. These drugs have been shown to induce atrophy of the seminiferous tubules of the t...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: HU (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2004-002686-21 Sponsor Protocol Number: Bosentan1 Start Date*: 2005-02-22
    Sponsor Name:Dept of Dermatology
    Full Title: Efficacy of Endothelin 1 receptor antagonist Bosentan in secondary Raynauds Syndrom
    Medical condition: secondary Raynauds Syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-003133-33 Sponsor Protocol Number: EMG-2006 Start Date*: 2006-07-14
    Sponsor Name:Hôpital Erasme
    Full Title: Etude des effets d’un antagoniste non spécifique de l’endothéline (le bosentan) sur l’activité orthosympathique et le chémoréflexe.
    Medical condition: healthy subjects obstructive sleep apnea (Bosentan is used in clinic in pulmonary hypertension)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002358-38 Sponsor Protocol Number: RET-D-001 Start Date*: 2015-04-28
    Sponsor Name:Travere Therapeutics, Inc.
    Full Title: PROTOCOL RET-D-001: EFFICACY AND SAFETY OF SPARSENTAN (RE-021), A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, IN PATIENTS WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS): A RANDOMIZED...
    Medical condition: FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10067757 Focal segmental glomerulosclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001131-31 Sponsor Protocol Number: FHC-1-2012 Start Date*: 2012-06-14
    Sponsor Name:Department of Medical Research
    Full Title: Effekts of nebivolol on the nitric oxide system in patients with essentiel hypertension
    Medical condition: Essential Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-001412-38 Sponsor Protocol Number: CQCC374X2201 Start Date*: 2017-07-27
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, parallel-group, placebo-controlled subject and investigator blinded study to assess the safety, tolerability, pharmacokinetics and efficacy of QCC374 in the treatment of pulmonary art...
    Medical condition: Pulmonary arterial hypertension
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-002686-30 Sponsor Protocol Number: CEP-AZ-SH-02 Start Date*: 2009-04-15
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-002623-42 Sponsor Protocol Number: 66623 Start Date*: 2019-02-18
    Sponsor Name:Academic Medical Center
    Full Title: Vasospastic angina treatment by Endothelin Receptor Antagonism; a proof of concept study
    Medical condition: Vasospastic angina, i.e. epicardial vasospasm or microvascular coronary dysfunction.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10002383 Angina pectoris PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005896-14 Sponsor Protocol Number: Version 1.0 Start Date*: 2006-02-20
    Sponsor Name:Department of Clinical Pharmacology
    Full Title: Role of endothelin- and nitric oxide-system in the regulation of optic nerve head blood flow during changes in ocular perfusion pressure
    Medical condition: 18 healthy male volunteers Age 18-35 yrs., nonsmokers
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 30 04:55:05 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA